Endometrial carcinoma: Molecular alterations involved in tumor development and progression

Oncogene

Volumn 32, Issue 4, 2013, Pages 403-413

  Yeramian, A ^a   Moreno Bueno, G ^b   Dolcet, X ^a   Catasus, L ^c   Abal, M ^d   Colas, E ^e   Reventos, J ^e   Palacios, J ^f   Prat, J ^c   Matias Guiu, X ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b CSIC   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

catenin; apoptosis; chromosomal instability; endometrial carcinoma; genetics; microsatellite instability; molecular alterations

Indexed keywords

APOPTOSIS; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CELL HYPOXIA; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; CTNNB1 GENE; ENDOMETRIUM CARCINOMA; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; IONIZING RADIATION; MICROSATELLITE INSTABILITY; MIXED MULLERIAN TUMOR; MYOMETRIUM; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; PROMOTER REGION; PTEN GENE; REVIEW; SIGNAL TRANSDUCTION; TP53 GENE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS;

EID: 84873059633     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.76     Document Type: Review

References (87)

1. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17.
2. Matias-Guiu X, Catasú s L, Bussaglia E, Lagarda H, Garcia A, Pons C et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32: 569-577.
3. Prat J, Gallardo A, Cuatrecasas M, Catasú s L. Endometrial carcinoma: Pathology and genetics. Pathology 2007; 39: 72-87.
4. Llobet D, Pallares J, Yeramian A, Santacana M, Eritja N, Velasco A et al. Molecular pathology of endometrial carcinoma; practical aspects from the diagnostic and therapeutical view points. J Clin Pathol 2009; 62: 777-785.
5. Duggan BD, Felix JC, Muderspach LI, Tourgeman D, Zheng J, Shibata D. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 1994; 86: 1216-1221.
6. Kobayashi K, Sagae S, Kudo H, Koi S, Nakamura Y. Microsatellite instability in endometrial carcinomas: frequent replication errors in tumors of early onset and/or of poorly differentiated type. Genes Chromosom Cancer 1995; 14: 128-132.
7. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993; 53: 5100-5103.
8. Catasú s L, Machin P, Matias-Guiu X, Prat J. Microsatellite instability in endometrial carcinomas clinicopathologic correlations in a series of 42 cases. Human Pathol 1998; 29: 1160-1164.
9. Esteller M, Catasú s Ll, Matias-Guiu X, Mutter GL, Prat J, Baylin SB et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999; 155: 1767-1772.
10. Catasú s L, Matias-Guiu X, Machin P, Mun? oz J, Prat J. BAX somatic framshift mutations in endometrioid adenocarcinomas of the endometrium: Evidence for a tumor progression role in endometrioid carcinomas with microsatellite instability. Lab Invest 1998; 78: 1439-1444.
11. Catasú s L, Matias-Guiu X, Machin P, Zannoni GF, Scambia G, Benedetti Panici PL et al. Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinomas with microsatellite instability. Cancer 2000; 88: 2290-2297.
12. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92: 924-931.
13. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57: 3935-3940.
14. Bussaglia E, del Rio E, Matias-Guiu X, Prat J. PTEN mutations in endometrial carcinomas. A molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000; 31: 312-317.
15. Nagase S, Sato S, Tezuka F, Wada Y, Yajima A, Horii A. Deletion mapping on chromosome 10q25-q26 in human endometrial cancer. Br J Cancer 1996; 74: 1979-1983.
16. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128: 157-170.
17. Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010; 2: 53ra75.
18. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005; 65: 10669-10673.
19. Velasco A, Bussaglia E, Pallares J, Dolcet X, Llobet D, Encinas M et al. PIK3CA gene mutations in endometrial carcinoma: Correlation with PTEN and K-RAS alterations. Hum Pathol 2006; 37: 1465-1472.
20. Catasú s L, Gallardo A, Cuatrecasas M, Prat J. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 2008; 21: 131-139.
21. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011; 17: 1331-1340.
22. Catasú s L, Gallardo A, Cuatrecasas M, Prat J. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 2009; 22: 522-529.
23. Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol 2009; 113: 370-373.
24. Catasú s L, D'Angelo E, Pons C, Espinosa I, Prat J. Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Mod Pathol 2010; 23: 694-702.
25. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M. Bell DW PIK3R1 (p85a) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 2011; 71: 4061-4067.
26. Milam MR, Celestino J, Wu W, Broaddus RR, Schmeler KM, Slomovitz BM et al. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol 2007; 196: 247.e1-5.
27. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al. NVPBEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-8030.
28. Lagarda H, Catasú s L, Argu? elles R, Matias-Guiu X, Prat J. K-ras mutations in endometrial carcinoma with microsatellite instabilit. J Pathol 2001; 193: 193-199.
29. Moreno-Bueno G, Sanchez-Estevez C, Palacios J, Hardisson D, Shiozawa T. frequency of BRAF mutations in endometrial and in cervical carcinomas. Clin Cancer Res 2006; 12: 3865.
30. Pallaré s J, Velasco A, Eritja N, Santacana M, Dolcet X, Cuatrecasas M et al. hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol 2008; 21: 691-699.
31. Velasco A, Pallares J, Santacana M, Gatius S, Fernandez M, Domingo M et al. Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma. Hum Pathol 2011; 42: 185-193.
32. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Mohammadi M et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007; 26: 7158-7162.
33. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C et al. Drugsensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008; 105: 8713-8717.
34. Gatius S, Velasco A, Azueta A, Santacana M, Pallares J, Valls J et al. FGFR-2 alterations in endometrial carcinoma. Mod Pathol 2011; 24: 1500-1510.
35. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. Betacatenin mutations in carcinoma of the uterine endometrium. Cancer Res 1998; 58: 3526-3528.
36. Kobayashi K, Sagae S, Nishioka Y, Tokino T, Kudo R. Mutations of the beta-catenin gene in endometrial carcinomas. Jpn J Cancer Res 1999; 90: 55-59.
37. Machin P, Catasú s L, Pons C, Mun? oz J, Matias-Guiu X, Prat J. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Human Pathol 2002; 33: 206-212.
38. Palacios J, Moreno-Bueno G, Catasú s L, Matias-Guiu X, Prat J, Gamallo C. Beta and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. Virchows Arch 2001; 193: 193-199.
39. Moreno-Bueno G, Hardisson D, Sa'nchez C, Sarrió D, Cassia R, Garci'a-Rosta'n G et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002; 21: 7981-7990.
40. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. P53 gene mutations are common in uterine serous carcinoma and occurs early in their pathogenesis. Am J Pathol 1997; 150: 177-185.
41. Sherman ME, Bur ME, Kurman RJ. P53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis. Human Pathol 1995; 26: 1268-1274.
42. Hayes MP, Ellenson LH. Molecular alterations in uterine serous carcinoma. Gynecol Oncol 2010; 116: 286-289.
43. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L et al. HER-2 is an independent prognostic factor in endometrial cancer: Association with outcome in a large cohort of surgically staged patients. J Clin Oncol 2006; 24: 2376-2385.
44. Tritz D, Pieretti M, Turner S, Powell D. Loss of heterozygosity in usual and special variant carcinomas of the endometrium. Hum Pathol 1997; 28: 607-612.
45. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. Frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: Evidence of distinct molecular genetic pathways. Cancer 2000; 88: 814-824.
46. Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 2011; 35: 625-632.
47. Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011; 224: 328-333.
48. Risinger JI, Maxwell GL, Chandramouli GV, Jazaeri A, Aprelikova O, Patterson T et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003; 63: 6-11.
49. Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M et al. Trefoil factor 3: A novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Brit J Cancer 2008; 99: 768-773.
50. Dainty LA, Risinger JI, Morrison C, Chandramouli GV, Bidus MA, Zahn C et al. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol 2007; 105: 563-567.
51. Allard JE, Risinger JI, Morrison C, Young G, Rose GS, Fowler J et al. Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol Oncol 2007; 107: 52-57.
52. Moreno-Bueno G, Sa'nchez-Este'vez C, Cassia R, Rodri'guez-Perales S, Di'az-Uriarte R, Domi'nguez O et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003; 63: 5697-5702.
53. Maxwell GL, Chandramouli GV, Dainty L, Litzi TJ, Berchuck A, Barrett JC et al. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res 2005; 11: 4056-4066.
54. Cao QJ, Belbin T, Socci N, Balan R, Prystowsky MB, Childs G et al. Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int J Gynecol Pathol 2004; 23: 321-329.
55. Shedden KA, Kshirsagar MP, Schwartz DR, Wu R, Yu H, Misek DE et al. type, organ of origin, and Wnt pathway status: Effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 2005; 11: 2123-2131.
56. Chen Y, Yao Y, Zhang L, Li X, Wang Y, Zhao L et al. cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer. Exp Mol Pathol 2011; 91: 373-384.
57. Risinger JI, Maxwell GL, Chandramouli GV, Aprelikova O, Litzi T, Umar A et al. Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling. Cancer Res 2005; 65: 5031-5037.
58. Yao Y, Chen Y, Wang Y, Li X, Wang J, Shen D et al. Molecular classification of human endometrial cancer based on gene expression profiles from specialized microarrays. Int J Gynaecol Obstet 2010; 110: 125-129.
59. Huvila J, Brandt A, Rojas CR, Pasanen S, Talve L, Hirsima? ki P et al. Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors. Int J Gynecol Cancer 2009; 19: 1226-1231.
60. Planaguma J, Di'az-Fuertes M, Gil-Moreno A, Abal M, Monge M, Garci'a A et al. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res 2004; 64: 8846-8853.
61. Soslow RA. Endometrial carcinomas with ambiguous features. Semin Diagn Pathol 2010; 27: 261-273.
62. Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA. Endometrial and ovarian carcinomas with undifferentiated components: Clinically aggressive and frequently underrecognized neoplasms. Mod Pathol 2010; 23: 781-789.
63. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002; 12: 687-690.
64. Lopez-Garcia MA, Palacios J. Pathologic and molecular features of uterine carcinosarcomas. Semin Diagn Pathol 2010; 27: 274-286.
65. Matias-Guiu X, Oliva E. Pathology of the endometrium. Semin Diagn Pathol 2010; 27: 197-198.
66. Castilla MÁ, Moreno-Bueno G, Romero-Pé rez L, De Vijver KV, Biscuola M, Ló pez-Garci'a MÁ et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol 2011; 223: 72-80.
67. Romero-Pérez L, Castilla MÁ, Ló pez-García MA, Díaz-Martín J, Biscuola M, Ramiro-Fuentes S et al. HMGA2 and epithelial-mesenchymal transition in endometrial carcinogenesis. (submitted).
68. Blechschmidt K, Kremmer E, Hollweck R, Mylonas I, Ho? fler H, Kremer M et al. The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn Mol Pathol 2007; 16: 222-228.
69. Montserrat N, Mozos A, Llobet D, Dolcet X, Pons C, de Herreros AG et al. Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Hum Pathol 2012; 43: 632-643.
70. Llaurado M, Abal M, Castellvi J, Cabrera S, Gil-Moreno A, Perez-Benavente A et al. ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. Int J Cancer 2011; 130: 1532-1543.
71. Monge M, Colas E, Doll A, Gonzalez M, Gil-Moreno A, Planaguma J et al. ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res 2007; 67: 6753-6759.
72. Planaguma J, Liljestrom M, Alameda F, Butzow R, Virtanen I, Reventos J et al. Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum Pathol 2011; 42: 57-67.
73. Espinosa I, Carnicer MJ, Catasú s L, Canet B, D'Angelo E, Zannoni GF et al. Myometrial invasion and lymph node metastasis in endometrioid carcinomas: Tumor-associated macrophages, microvessel density, and HIF1A have a crucial role. Am J Surg Pathol 2010; 34: 1708-1714.
74. Monge M, Doll A, Colas E, Gil-Moreno A, Castellvi J, Garcia A et al. Subtractive proteomic approach to the endometrial carcinoma invasion front. J Proteome Res 2009; 8: 4676-4684.
75. Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J et al. Abnormalities in NF-kB family and related proteins in endometrial carcinoma. A tissue microarray study. J Pathol 2004; 13: 569-577.
76. Dolcet X, Llobet D, Pallares J, Rue M, Comella JX, Matias-Guiu X. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 2005; 85: 885-894.
77. Llobet D, Eritja N, Domingo M, Bergada L, Mirantes C, Santacana M et al. Dolcet KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. Am J Pathol 2011; 178: 1529-1543.
78. Llobet D, Eritja N, Encinas M, Yeramian A, Pallares J, Sorolla A et al. The multikinase inhibitor sorafenib induces apoptosis and sensitizes endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer 2010; 46: 836-850.
79. Llobet D, Eritja N, Encinas M, Yeramian A, Pallares J, Sorolla A et al. CK2 controls trail and Fas sensitivity by regulating flip levels in endometrial carcinoma cells. Oncogene 2008; 27: 2513-2524.
80. Pallares J, Llobet D, Santacana M, Eritja N, Velasco A, Cuevas D et al. CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation. Am J Pathol 2009; 174: 287-296.
81. Dolcet X, Llobet D, Encinas M, Pallares J, Cabero A, Schoenenberger JA et al. Proteasome inhibitors induce death but activate NF-KB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 2006; 281: 22118-22130.
82. Pijnenborg JM, Romano A, Dam-de Veen GC, Dunselman GA, Fischer DC, Groothuis PG et al. Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma. J Pathol 2005; 205: 597-605.
83. Pijnenborg JM, Dam-de Veen GC, de Haan J, van Engeland M, Groothuis PG. Defective mismatch repair and the development of recurrent endometrial carcinoma. Gynecol Oncol 2004; 94: 550-559.
84. Pijnenborg JM, van de Broek L, Dam de Veen GC, Roemen GM, de Haan J, van Engeland M et al. TP53 overexpression in recurrent endometrial carcinoma. Gynecol Oncol 2006; 100: 397-404.
85. Pijnenborg JM, Kisters N, van Engeland M, Dunselman GA, de Haan J, de Goeij AF et al. APC, beta-catenin, and E-cadherin and the development of recurrent endometrial carcinoma. Int J Gynecol Cancer 2004; 14: 947-956.
86. Santacana M, Yeramian A, Velasco A, Bergada L, Garci'a V, Azueta A et al. Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium. Role for proteins involved in resistance to apoptosis and hypoxia. Histopathology 2012; 60: 460-471.
87. Yeramian A, Santacana M, Sorolla A, Llobet D, Encinas M, Velasco A et al. Nuclear factor beta /p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1alpha in an independent manner. Lab Invest 2011; 91: 859-871.